Abstract
The monoclonal antibody 2F5 recognizing the neutralizing epitope ELDKWA on the C-domain could neutralize 90% of the investigated HIV-1 isolates. Low levels of ELDKWA-epitope-specific antibodies were observed in HIV-1-infected individuals. To induce high levels of antibodies to ELDKW-epitope, C-domain peptide (P2) was conjugated with a carrier peptide (KGGG)7-K (K/G). P2-K/G-conjugate induced high level of antibodies in mice by titer 1:25 600 to ELDKWA-epitope. P2-K/G-BSA-conjugate induced antibody response to ELDKWA-epitope (1:320-6400) in mice. The ELDKWA-epitope-specific antibodies of 19.8 and 34.6 μg/per milliliter serum were isolated from two rabbit antiserums (1:25 600). The levels of ELDKWA-epitope-specific antibodies induced in rabbits were greater than 1 μg/ml, a level considered to confer long-term protection. These results demonstrate the potential role of the C-domain peptide of gp41 to develop an effective ELDKWA-based epitope/peptide-vaccine against HIV-1. Copyright (C) 2000 Elsevier Science Inc.
Original language | English (US) |
---|---|
Pages (from-to) | 463-468 |
Number of pages | 6 |
Journal | Peptides |
Volume | 21 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2000 |
Externally published | Yes |
Keywords
- Epitope-vaccine
- HIV-1 gp41
- Neutralizing epitope
ASJC Scopus subject areas
- Biochemistry
- Physiology
- Endocrinology
- Cellular and Molecular Neuroscience